Skip to content
    AMGN
    Earnings call· Jun 2026(Q2 FY26)

    AMGEN Q2 FY26 earnings call AMGN

    Aug 4, 2026 Source

    Executive summary

    Amgen Q2 FY26 — Strong Portfolio Performance and Raised Full-Year Guidance

    Amgen delivered robust Q2 FY26 results, driven by strong performance across its diversified portfolio of innovative medicines and biosimilars, particularly its six key growth drivers. The company raised its full-year revenue and non-GAAP EPS guidance, reflecting confidence in its pipeline advancements, including MariTide and Olpasiran, and continued operational execution. Strategic investments in R&D and manufacturing capacity are aimed at sustaining long-term growth well into the next decade.

    Highlights

    5
    • Total revenues exceeded $10 billion, a 10% year-over-year increase.

    • Six key growth drivers (Repatha, EVENITY, TEZSPIRE, Rare Disease, Innovative Oncology, Biosimilars) grew at an aggregate rate of 26% year-over-year, representing nearly 70% of product sales.

    • Repatha sales grew 37% year-over-year to $953 million, with new-to-brand prescriptions up over 50% in the U.S.

    • UPLIZNA sales increased 90% year-over-year to $335 million, reflecting sustained momentum across all 3 approved indications.

    • Biosimilar portfolio delivered 29% year-over-year growth, generating $855 million in sales, with PAVBLU up 121% to $287 million.

    Concerns

    3
    • Prolia and XGEVA combined sales decreased 33% year-over-year to $1.1 billion due to biosimilar competition.

    • AMG 513, a Phase I obesity asset, was discontinued from development.

    • Otezla is experiencing some pressure on price due to 340B exposure.

    Guidance & targets

    9
    CategoryTargetConfidence
    Total Revenues
    $38.2 billion to $39.4 billion
    high materiality
    High
    Non-GAAP Earnings Per Share
    $22.30 to $23.50
    high materiality
    High
    Other Revenue
    approximately $1.9 billion
    medium materiality
    Medium
    Non-GAAP R&D Expense Growth
    high single digits year-over-year
    medium materiality
    Medium
    Non-GAAP Other Income and Expense
    $2.1 billion to $2.2 billion of expense
    medium materiality
    Medium
    Non-GAAP Operating Margin as a percentage of product sales
    roughly 45% to 46%
    medium materiality
    Medium
    Non-GAAP Tax Rate
    15.0% to 16.5%
    low materiality
    Medium
    Share Repurchases
    not to exceed $3 billion
    medium materiality
    Medium
    Capital Expenditures
    approximately $2.6 billion
    medium materiality
    High

    Segment performance

    12
    SegmentRevenueYoYQoQMargin
    Repatha
    Momentum continues to build with increased urgency to treat in both secondary and high-risk primary prevention. Supported by unrivaled clinical evidence, including VESALIUS-CV trial data.
    New-to-brand prescriptions (U.S.): >50% YoY growthPatients on therapy (U.S.): >1 millionLDL-C goals: 100 million patients worldwide still above goals
    $953 million37%
    EVENITY
    Building on previous quarter's growth, leading the U.S. bone builder market and holding category leadership in Japan. Significant opportunity remains in the U.S. with approximately 2 million women at very high risk of fracture.
    U.S. penetration: mid-single-digitJapan volume share: >55%Patients treated (Japan): 1 million
    $714 million38%
    TEZSPIRE
    Driven by strong demand in severe uncontrolled asthma, with growing adoption among pulmonologists. Encouraging uptake in chronic rhinosinusitis with nasal polyps. Additional indications expected to drive future growth.
    New-to-brand prescription share (severe uncontrolled asthma, allergists): market leaderMedicare access: expanded
    $486 million42%
    Rare Disease
    Growth driven by additional indications, international expansion, and disciplined pricing, contributing to Amgen's long-term growth.
    $1.6 billion21%
    UPLIZNA
    Reflecting sustained momentum across all 3 approved indications (NMOSD, myasthenia gravis, IgG4-related disease). Strong efficacy, durable benefit, and convenient twice-yearly dosing are resonating with physicians and patients. Well-positioned for market leadership in gMG.
    U.S. prescribers (gMG): doubled since previous quarter
    $335 million90%
    TEPEZZA
    Strong global uptake, particularly in Japan. Expanding awareness and prescriber base (endocrinologists, ophthalmologists). Advancement of subcutaneous on-body injector expected to drive long-term growth.
    Countries launched: 13Planned country launches: 6 (in coming months)Patients treated (U.S. since approval): >25,000
    $576 million14%
    Innovative Oncology
    Portfolio growth driven by strong performance of IMDELLTRA and BLINCYTO, expanding the BiTE platform across tumor types and earlier lines of treatment.
    $2 billion18%
    IMDELLTRA
    Emerging as best-in-class for second-line small cell lung cancer, with strong clinical conviction and rapid adoption. Significant opportunity to further penetrate the second-line patient population. Data in first-line extensive stage small cell lung cancer expected to expand impact.
    U.S. accounts using: >2,000
    $288 million115%
    BLINCYTO
    Driven by broad prescribing in the U.S. and strong international performance, particularly in Europe and Japan, due to broader first-line adoption and robust treatment duration.
    International growth: 64%
    $472 million23%
    Biosimilars
    Strong growth driven by adoption of existing biosimilars. Next wave of biosimilar candidates for EYLEA HD, OPDIVO, KEYTRUDA, and OCREVUS are in late-stage clinical development.
    Total sales since 2018: >$15 billion
    $855 million29%
    PAVBLU
    Adoption expanding among retina specialists due to ready-to-use prefilled syringe format and Amgen's quality track record.
    $287 million121%
    Prolia and XGEVA (combined)
    Sales decrease in line with expectations due to the launch of several biosimilar competitors.
    $1.1 billion-33%

    Operational metrics

    13
    Non-GAAP Operating Margin
    48%
    Q2 FY26

    Reflects strong operating results while increasing investment in innovation.

    Non-GAAP R&D Spending
    10%YoY increase
    Q2 FY26

    Reflects continued investment in innovation, including MariTide, Xaluritamig, Olpasiran, UPLIZNA, TEZSPIRE, and IMDELLTRA.

    Non-GAAP Cost of Sales as a percentage of product sales
    19.6%YoY increase
    Q2 FY26

    Year-over-year increase primarily reflected higher profit sharing and royalty expenses, as well as changes in sales mix.

    Capital Expenditures
    $500 million
    Q2 FY26

    Driven by investments to scale manufacturing capacity for volume growth, including for MariTide's launch.

    Dividend Per Share
    $2.526% increase compared to Q2 FY25
    Q2 FY26

    Return of capital to shareholders.

    MariTide Phase III Studies
    9 ongoing and 3 additional planned
    Ongoing

    Across obesity and related serious chronic diseases, guiding how to start, stay on, and switch to MariTide.

    Olpasiran Lp(a) Reduction
    >95%
    Phase II

    Demonstrated in Phase II, positioning Olpasiran for a potentially best-in-class profile.

    Dazodalibep Systemic Study Enrollment
    621
    Phase III

    Enrollment for the systemic Sjögren's disease study.

    Dazodalibep Symptomatic Study Enrollment
    434
    Phase III

    Enrollment for the symptomatic Sjögren's disease study.

    IMDELLTRA Addressable Patients
    as many as 28,000
    U.S.

    Potential addressable patient population in the U.S. if IMDELLTRA expands into earlier treatment lines.

    Otezla Volume
    holding up quite good
    Q2 FY26

    Despite new entrants, Otezla is generally used as a first-stop systemic agent, with new entrants competing after Otezla has been tried.

    MariTide Half-life
    approximately 21 days
    Ongoing

    Due to its antibody design, allowing for extended dosing.

    IMDELLTRA Monitoring Reduction
    1 to 2 hoursvs 16 hours in Phase III
    Real-world/Ongoing clinical study

    Reduced monitoring observed in real-world and ongoing clinical studies, compared to the initial 16 hours in Phase III, due to infrequent ICANS.

    Industry KPIs

    8
    MetricValueDetails
    Launch access metricsexpanded
    Pipeline read out calendar9 ongoing and 3 additional planned Phase III studiesstudies
    Product franchise net sales$953 millionUSD
    Regulatory approvals filingsPositive CHMP opinion
    Therapeutic drug market sharemid-single-digit penetration%
    Prescription volume new starts>50%%
    Clinical trial efficacy safety data29% reduction%
    Cumulative patients uptake since launch>1 millionpeople

    Deals & partnerships

    1
    UndisclosedBusiness development transaction$100 million

    A business development transaction resulting in a $100 million upfront payment.

    Risks & headwinds

    2
    Biosimilar competitionQ2 FY26

    Prolia and XGEVA sales decreased 33% year-over-year to $1.1 billion.

    Mitigation: Focus on growth drivers, pipeline advancements, and next wave of biosimilars to offset impact.

    Otezla pricing pressureOngoing

    Some pressure on price

    Mitigation: Leveraging extensive clinical experience, broad label, and clear payer coverage for Otezla as a first-stop systemic agent. Volume is holding up.

    What to watch in Q3 FY26

    5

    Dazodalibep Phase III Results

    H2 FY26
    CurrentPhase III studies ongoing for systemic and symptomatic Sjögren's disease
    TargetResults from two dedicated Phase III studies

    Why it matters

    These results will determine the potential for Dazodalibep in a challenging and unmet need area, impacting Amgen's rare disease pipeline.

    Results are expected later this year.

    Q&A highlights

    7

    Inquired about the protocol design for Olpasiran's Phase III studies, specifically regarding interim analyses and the impact of using a MACE-3 endpoint (excluding strokes) compared to MACE-4 on study duration.

    Amgen's OCEAN(a) study for Olpasiran is a double-blind, randomized controlled trial with 7,297 patients. It requires Lp(a) elevations above 200 nanomoles per liter and uses a 3-point MACE endpoint. The exclusion of ischemic stroke from the endpoint was based on human genetics and population science indicating a less compelling association with Lp(a) elevation, and Amgen's modeling suggests it does not affect the event rate.

    We focused on 3-point MACE after extensive human genetics and population science analysis indicated to us that the association of ischemic stroke and Lp(a) elevation was not as compelling as other cardiac-specific cardiovascular endpoints. And this is, therefore, a potentially important distinction between this study and others.

    asked by Dina Elmonshed · answered by James Bradner

    3 min read7 chapters

    Detailed Narrative

    01

    Portfolio Strength and Growth Drivers

    Amgen's Q2 FY26 performance was driven by the breadth and depth of its portfolio, with 22 products achieving double-digit sales growth and 17 products annualizing at over $1 billion. Six key growth drivers—Repatha, EVENITY, TEZSPIRE, Rare Disease, Innovative Oncology, and Biosimilars—collectively grew 26% year-over-year and accounted for nearly 70% of product sales. This broad-based performance underscores the company's strategy to deliver durable growth despite patent expirations and increased competition.

    02

    Cardiovascular and Cardiometabolic Pipeline Advancements

    Amgen is advancing its leadership in cardiovascular disease with Repatha, Olpasiran, and MariTide. Repatha, the only PCSK9 inhibitor with Phase III outcomes data in both primary and secondary prevention, continues to see strong momentum. Olpasiran, targeting Lp(a), is in two Phase III outcome studies, positioned for a best-in-class profile with >95% Lp(a) reduction. MariTide, a differentiated GLP-1 therapy, is progressing rapidly with 9 ongoing and 3 planned Phase III studies across obesity and related diseases, aiming for monthly or less frequent dosing.

    03

    Rare Disease Portfolio Expansion

    The Rare Disease portfolio grew 21% year-over-year to $1.6 billion, driven by additional indications and international expansion. UPLIZNA sales increased 90%, reflecting sustained momentum across NMOSD, myasthenia gravis, and IgG4-related disease. The company is extending UPLIZNA's impact with new registrational studies in autoimmune hepatitis and chronic inflammatory demyelinating polyneuropathy. Dazodalibep for Sjögren's disease is also in two Phase III studies, with results expected later this year.

    04

    Oncology and Inflammation Progress

    Innovative Oncology grew 18% year-over-year, generating $2 billion in sales. IMDELLTRA sales increased 115%, establishing itself as a best-in-class treatment for second-line small cell lung cancer, with efforts underway to expand into earlier treatment lines and more convenient administration. BLINCYTO sales grew 23%, driven by broad prescribing in the U.S. and international adoption. TEZSPIRE sales grew 42% in severe uncontrolled asthma, with encouraging uptake in chronic rhinosinusitis with nasal polyps and a Phase III study in eosinophilic esophagitis expected to complete in H2.

    05

    Biosimilars and Future Growth

    Amgen's biosimilar portfolio delivered 29% year-over-year growth, reaching $855 million in sales. PAVBLU, a biosimilar to EYLEA, saw sales increase 121%. The company highlights its biologics expertise and manufacturing scale as differentiators. A next wave of biosimilar candidates for EYLEA HD, OPDIVO, KEYTRUDA, and OCREVUS are in late-stage clinical development, representing significant future market opportunities and patient access expansion.

    06

    Financial Discipline and Capital Allocation

    The company reported a non-GAAP operating margin of 48% and generated $3.5 billion in free cash flow in Q2. Non-GAAP R&D spending increased 10% year-over-year, reflecting continued investment in the pipeline and marketed medicines. Capital expenditures of $500 million were driven by investments in U.S. manufacturing sites to scale capacity, particularly for MariTide's launch. Amgen returned capital to shareholders through dividends and expects share repurchases not to exceed $3 billion for the full year.

    07

    Technology and AI Integration

    Amgen is strategically applying AI across discovery, development, manufacturing, and access to medicines. The company has established a frontier AI laboratory to combine advanced models with proprietary data and scientific capabilities, aiming to augment insights and accelerate research. These investments are already proving valuable in advancing promising medicines more efficiently.

    AI-generated summary of the company’s earnings call. Not investment advice.